{"id":528621,"date":"2021-02-03T08:02:02","date_gmt":"2021-02-03T08:02:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=528621"},"modified":"2021-02-03T08:02:02","modified_gmt":"2021-02-03T08:02:02","slug":"nonhodgkins-lymphoma-pipeline-emerging-therapies-and-drugs-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonhodgkins-lymphoma-pipeline-emerging-therapies-and-drugs-by-delveinsight_528621.html","title":{"rendered":"Non-Hodgkin’s Lymphoma Pipeline, Emerging therapies and Drugs by DelveInsight"},"content":{"rendered":"

DelveInsight<\/strong> has launched a new report on “Non-Hodgkin’s Lymphoma Pipeline<\/a>”<\/strong><\/p>\n

 <\/p>\n

NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin’s disease. Commonly the NHL occurs from lymph node at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can and can develop from either B-cells or T-cells or Natural killer (NK) cells.<\/p>\n

 <\/p>\n

Request for free sample copy<\/strong>– https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight<\/a><\/strong><\/span><\/p>\n

 <\/p>\n

Non-Hodgkin’s Lymphoma Pipeline<\/strong> analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities<\/p>\n

 <\/p>\n

Non-Hodgkin’s Lymphoma Pipeline<\/strong><\/p>\n

According to the Leukemia and Lymphoma Society (2018), NHL subtypes include diffuse large B-cell lymphoma (DLBCL), Small-cell lymphocytic lymphoma SLL\/Chronic lymphocytic leukemia (CLL), Marginal zone lymphoma (MZL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Mantle cell lymphoma (MCL), Burkitt lymphoma (BL) and others. The cellular origin of B-cell lymphomas usually starts, when B cells undergo malignant transformation, they usually retain key features of their cell of origin, including specific characteristics of the particular differentiation stage of the lymphoma precursor.<\/p>\n

 <\/p>\n

Marketed drugs included in the report<\/strong><\/p>\n